Windtree Therapeutics, Inc. (NASDAQ:WINT) Short Interest Update

Windtree Therapeutics, Inc. (NASDAQ:WINT) saw a large decline in short interest in the month of April. As of April 15th, there was short interest totalling 2,600 shares, a decline of 93.5% from the March 31st total of 39,700 shares. Based on an average daily volume of 15,600 shares, the days-to-cover ratio is presently 0.2 days.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “neutral” rating on shares of Windtree Therapeutics in a research report on Wednesday, January 3rd.

Windtree Therapeutics Price Performance

Windtree Therapeutics stock opened at $5.07 on Friday. Windtree Therapeutics has a 52 week low of $4.78 and a 52 week high of $35.10. The business has a 50-day simple moving average of $6.54 and a 200 day simple moving average of $11.64. The company has a quick ratio of 1.35, a current ratio of 1.35 and a debt-to-equity ratio of 4.42. The stock has a market cap of $1.47 million, a price-to-earnings ratio of -0.04 and a beta of 0.61.

Windtree Therapeutics (NASDAQ:WINT) last posted its earnings results on Tuesday, April 16th. The company reported ($13.31) EPS for the quarter. On average, research analysts forecast that Windtree Therapeutics will post -25 earnings per share for the current fiscal year.

Windtree Therapeutics Company Profile

Windtree Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant, which is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19; Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activator, which is in preclinical trial for the treatment of chronic and acute heart failure.